The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
thanks for the post cjulien, what is people's take on the comments made in the Discussion section of the paper, where it refers to the formulation being used by Syn begin protected with patents and that the formulation in the french study possibly not being subject to the same market controls and mitigated by upping the dose due to it being less efficacious?
Am I right in thinking this was previously listed as 'in setup'? Now changed to 'open'
https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=290965
https://racetoacure.stanford.edu/development-leads/4
I came across this in a search - not sure if there is any link as the page is hard to interpret - Cadila and Synairgen mentioned as sponsors - not sure if it is the same project or both looking at Inf B - any thoughts? India link? Might be barking up a tree?
Didn't see this one first time around - did others?
https://www.youtube.com/watch?v=W1dA9VhL60A&list=PLQ_IRFkDInv-NvRRUN0aqe51sMs188k8z&index=38
Have a good evening all, be kind to one another, today of all days
B.
Back into research mode tonight:
Might be of interest to anyone wanting to keep up to speed with the range of trials - scroll down to the interferons section - SNG is in there - identified in the 'country' column as 'uk' and 'global'
https://covdb.stanford.edu/clinical-trials/
I see that this is also at home - anyone got views or done research on this one - some tweets this morning and their numbers recruited look good
https://twitter.com/JimBethell/status/1352187945365745664
More evidence that early intervention with Inf Beta could be the way to go with SNG study referred to and referenced as well.
https://www.nature.com/articles/d41586-021-00149-1?utm_source=Nature+Briefing&utm_campaign=57e66184c4-briefing-dy-20210120&utm_medium=email&utm_term=0_c9dfd39373-57e66184c4-45781214
https://www.news-medical.net/news/20210112/Researchers-identify-shorter-form-of-ACE2-that-lacks-SARS-CoV-2-binding-site.aspx
https://medicalxpress.com/news/2021-01-covid-drug-prospects-boosted-discovery.html
FayeConnie - I am aware of the trial Deets as I have held and have been following closely since well before the July rise so am lucky enough to be in a reasonable profit and with my original stake recovered so a lucky position to be in. I believe the long history of the drug data gives it low risk in terms of safety, the BOD are top notch with brains the size of Jupiter, they have done what they said they would do, give or take a day or two and are at the cutting edge of science. For me, in investment terms, this is now about logistics and political will - that's the news I am waiting on and i will certainly be sitting tight for now (and may top up more) if the stars align. ATB
thanks Mr B, makes sense - just need some news from SNG asap to assess risk v reward (again) as the target demographic for the vaccine will (hopefully) give relief to the most at risk first and trying to get my head around how that will impact on who SNG would benefit most. I am a LTH and just trying to weigh up the reality of getting the drug out there, unless SNG have started to stockpile already, against the likelihood of an EUA coming through shortly and speed at which vaccine roll outs can realistically take place. Hopefully an RNS shortly to fill some knowledge gaps for us all. Thanks to all for ongoing research and knowledge to help with informed decision making. GLA
Anyone got thoughts on the potential age range that could use SNG001 if an EUA lands? Do we think that it will be only in 55 plus due to the demographics in the trial? Just a thought, apols if already covered
SNG:
62.87 % bought
37.13% sold
https://www.hl.co.uk/shares
https://hospitalhealthcare.com/covid-19/inhaled-interferon-beta-shows-promise-as-covid-19-treatment/
another mention